Treatment of advanced medullary thyroid cancer

Thyroid Research

Volumn 6, Issue SUPPL.1, 2013, Pages

  Smit, Johannes ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875347365     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/1756-6614-6-S1-S7     Document Type: Review

References (32)

1. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RT, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr, Thyroid 2009 19 565 612 10.1089/thy.2008.0403 19469690
2. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Roman S, Lin R, Sosa JA, Cancer 2006 107 9 2134 42 10.1002/cncr.22244 17019736 (Pubitemid 44665646)
3. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M, J Clin Endocrinol Metab 2007 92 4185 4190 10.1210/jc.2007-1211 17726071 (Pubitemid 350074730)
4. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Giraudet AL, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger M, Eur J Endocrinol 2008 158 239 246 10.1530/EJE-07-0667 18230832 (Pubitemid 351298542)
5. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, J Clin Endocrinol Metab 2005 90 6077 6084 10.1210/jc.2005-0044 16091497 (Pubitemid 41606528)
6. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM, Ann Surg 1990 212 395 400 discussion 400-401 10.1097/00000658-199010000-00002 2222011
7. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M, Br J Cancer 2003 88 1537 1542 10.1038/sj.bjc.6600930 12771918 (Pubitemid 36713778)
8. Longterm outcome of reoperations for medullary thyroid carcinoma. Fialkowski E, Debenedetti M, Moley J, World J Surg 2008 32 754 765 10.1007/s00268-007-9317-7 18188643
9. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M, Shaha AR, Tuttle RM, Shah JP, Larson SM, J Nucl Med 2007 48 501 507 10.2967/jnumed.106.036681 17401085 (Pubitemid 47571403)
10. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP, J Nucl Med 2008 49 524 531 10.2967/jnumed.107.047720 18375923 (Pubitemid 351520599)
11. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Kebebew E, Kikuchi S, Duh QY, Clark OH, Arch Surg 2000 135 895 901 10.1001/archsurg.135.8.895 10922248 (Pubitemid 30625965)
12. Lymph node dissection and medullary thyroid carcinoma. Dralle H, Br J Surg 2002 89 1073 1075 10.1046/j.1365-2168.2002.02160.x 12190669 (Pubitemid 34989210)
13. Long-term outcome of reoperations for medullary thyroid carcinoma. Fialkowski E, Debenedetti M, Moley J, World J Surg 2008 32 754 765 10.1007/s00268-007-9317-7 18188643
14. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T, Thyroid 1996 6 305 310 10.1089/thy.1996.6.305 8875751 (Pubitemid 26303135)
15. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC, Cancer 2003 98 356 362 10.1002/cncr.11488 12872357 (Pubitemid 36828462)
16. Prognosis and treatment of brain metastases in thyroid carcinoma. Chiu AC, Delpassand ES, Sherman SI, J Clin Endocrinol Metab 1997 82 3637 3642 10.1210/jc.82.11.3637 9360519 (Pubitemid 27509349)
17. Single brain metastasis from thyroid cancer: report of twelve cases and review of the literature. Salvati M, Frati A, Rocchi G, Masciangelo R, Antonaci A, Gagliardi FM, Delfini R, J Neurooncol 2001 51 33 40 10.1023/A:1006468527935 11349878 (Pubitemid 32321899)
18. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, J Clin Endocrinol Metab 2001 86 1568 1573 10.1210/jc.86.4.1568 11297585 (Pubitemid 32374905)
19. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. Eustatia-Rutten CFA, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EPM, Pereira AM, Smit JW, J Clin Endocrinol Metab 2003 88 3184 3189 10.1210/jc.2003-030231 12843163 (Pubitemid 36877492)
20. Percutaneous vertebroplasty for metastatic involvement of the axis. MontAlverne F, Vallee JN, Cormier E, Guillevin R, Barragan H, Jean B, Rose M, Chiras J, AJNR Am J Neuroradiol 2005 26 1641 1645 16091507 (Pubitemid 43853657)
21. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G, Br J Cancer 2001 84 1586 1590 10.1054/bjoc.2001.1832 11401309 (Pubitemid 32612487)
22. Airway stenting for the treatment of laryngotracheal stenosis secondary to thyroid cancer. Tsutsui H, Kubota M, Yamada M, Suzuki A, Usuda J, Shibuya H, Miyajima K, Sugino K, Ito K, Furukawa K, Kato H, Respirology 2008 13 632 638 10.1111/j.1440-1843.2008.01309.x 18513246 (Pubitemid 351977581)
23. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Wertenbroek MW, Links TP, Prins TR, Plukker JT, van der Jagt EJ, de Jong KP, Thyroid 2008 18 1105 1110 10.1089/thy.2008.0080 18816179
24. Chemoembolization for liver metastases from medullary thyroid carcinoma. Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M, J Clin Endocrinol Metab 2006 91 2496 2499 10.1210/jc.2005-2401 16608897 (Pubitemid 44024606)
25. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R, Nat Rev Endocrinol 2011 7 10 617 24 10.1038/nrendo.2011.141 21862995
26. New treatment modalities in advanced thyroid cancer. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, Smit JW, Ann Oncol 2012 23 1 10 8 10.1093/annonc/mdr117 21471561
27. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (ZETA). Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ, J Clin Oncol 2012 30 134 141 10.1200/JCO.2011.35.5040 22025146
28. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline [abstract]. Schoffski P, Elisei R, Müller S, Brose MS, Shah MH, Licitra LF, Jarzab B, Medvedev V, Kreissl M, Niederle B, Cohen EEW, Wirth LJ, Ali HY, Hessel C, Yaron Y, Ball DW, Nelkin B, Sherman SI, Schlumberger M, J Clin Oncol 2012 30 15-suppl 5508
29. Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Kraeber-Bodere F, Goldenberg DM, Chatal JF, Barbet J, Curr Oncol 2009 16 3 8 19862356
30. The palliative role of 131 I-MIBG and 111 In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Pasieka JL, McEwan AJ, Rorstad O, Surgery 2004 136 1218 1226 10.1016/j.surg.2004.06.050 15657579 (Pubitemid 39647537)
31. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Jensen RT, Semin Gastrointest Dis 1999 10 156 172 10548409 (Pubitemid 29506140)
32. Ectopic adrenocorticotropic hormone syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. Barbosa SL, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps JL, Caron P, Archambeaud-Mouveroux F, Conte-Devolx B, Rohmer V, Thyroid 2005 15 618 623 10.1089/thy.2005.15.618 16029131 (Pubitemid 40993738)